Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics Inc (NQ: VTGN )

4.718 -0.112 (-2.32%)
Streaming Delayed Price Updated: 2:35 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 117,322
Open 4.850
Bid (Size) 4.700 (4)
Ask (Size) 4.740 (2)
Prev. Close 4.830
Today's Range 4.650 - 4.860
52wk Range 1.620 - 24.71
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
Explore three stocks under $10 in electronic equipment and instruments, technology hardware, storage and peripherals, and biotechnology. 
Via InvestorPlace

Performance

YTD
-8.39%
-8.39%
1 Month
+10.23%
+10.23%
3 Month
-4.69%
-4.69%
6 Month
+58.32%
+58.32%
1 Year
+11.22%
+11.22%

More News

Read More
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference
Via Investor Brand Network
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
From Vistagen
Via Business Wire
Recap: Vistagen Therapeutics Q3 Earnings
Via Benzinga
VistaGen Therapeutics's Earnings: A Preview
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
Via Investor Brand Network
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
From Vistagen
Via Business Wire
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
Via InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
Via Investor Brand Network
Vistagen to Present at Stifel 2024 Virtual CNS Days
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
Via Investor Brand Network
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
From Vistagen
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Revolutionary Biotech Stocks Poised for 10X Surge
Via InvestorPlace
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
Via InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Earnings Scheduled For February 13, 2024
Via Benzinga
3 Penny Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
Via Investor Brand Network
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
From Vistagen
Via Business Wire
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
Via InvestorPlace
Topics Economy
Exposures Economy
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.